Australien - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: gelatin; fumaric acid; stearic acid; pregelatinised maize starch; titanium dioxide; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolis is indicated for the treatment of relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis with superimposed relapses to delay the progression of physical disability and reduce the frequency of relapse.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fingolimod hydrochloride, quantity: 0.28 mg (equivalent: fingolimod, qty 0.25 mg) - capsule, hard - excipient ingredients: mannitol; hyprolose; hydroxypropylbetadex; magnesium stearate; shellac; iron oxide black; propylene glycol; gelatin; strong ammonia solution; titanium dioxide; iron oxide yellow - fingolimod sandoz is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: mannitol; iron oxide yellow; magnesium stearate; gelatin; titanium dioxide - fingolimod sandoz is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: mannitol; iron oxide yellow; magnesium stearate; gelatin; titanium dioxide - gilenya is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Malta - engelsk - Malta Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - topiramate - hard capsule - topiramate 50 mg - antiepileptics

Malta - engelsk - Malta Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - topiramate - hard capsule - topiramate 25 mg - antiepileptics

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: magnesium stearate; calcium hydrogen phosphate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; iron oxide yellow; titanium dioxide; gelatin - pharmacor fingolimod is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty mg) - capsule, hard - excipient ingredients: magnesium stearate; calcium hydrogen phosphate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; iron oxide yellow; titanium dioxide; gelatin - akm fingolimod is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: gelatin; triethyl citrate; titanium dioxide; sucrose; brilliant blue fcf; hypromellose phthalate; purified talc; hypromellose; iron oxide yellow; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd). treatment of generalised anxiety disorder (gad).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose phthalate; triethyl citrate; brilliant blue fcf; purified talc; hypromellose; gelatin; titanium dioxide; sucrose; maize starch; propylene glycol; ethanol; indigo carmine; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd). treatment of generalised anxiety disorder (gad).